Novo Nordisk's Ozempic (semaglutide) has shown significant benefits in a clinical trial for patients with type 2 diabetes and chronic kidney disease. The FLOW trial demonstrated that weekly doses of semaglutide reduced the risk of major kidney events, cardiovascular events, and death from any cause. Additionally, the medication slowed the progression of kidney function decline. New data revealed that semaglutide cut the risk of clinically important kidney outcomes and death from cardiovascular causes. The findings were presented at the ERA24 conference.
